brain cancer news from FierceBiotech
News
Northwest Bio says it is running out of cash
Northwest Biotherapeutics startled investors with the news that it has only $1.1 million of cash on hand--enough to fund operations through September. And assurances that the developer is in talks Read more...
ALSO NOTED: New vaccine/chemo combo effective in cancer study; Type 1 diabetes vaccine goes into human studies; and much more..
> Chutes & Ladders: Susan Windham-Bannister will take over as CEO of the Massachusetts Life Sciences Center Board. The board's function is to ensure the state retains its prominence in the Read more...
Antigenics gets world's first cancer vaccine approval
Russia has improbably emerged as a world leader in new cancer vaccines. The country's regulatory body approved the use of Read more...
Peregrine reports positive cancer data
Peregrine Pharmaceuticals is posting positive data from two ongoing, mid-stage trials of its cancer therapy Cotara. The trial data assessed Cotara's safety and efficacy in treating patients with Read more...
Antigenics' cancer vax gets mixed Phase III results
Antigenics' cancer vaccine Oncophage failed to meet its primary endpoint of overall Read more...
ALSO NOTED: Avastin delivers promising data for brain cancer; Genelabs regains development rights; and much more...
> A mid-stage study of Avastin shows promising results in treating a form of brain cancer. Read more...
Avant, Celldex merge in $115M stock deal
Avant Immunotherapeutics is merging with Celldex Therapeutics in a stock deal valued at $115 million. Celldex shareholders will wind up with a majority of the shares in the merged company, which will Read more...
Press Release: Eli Lilly and Company Stops Trial Of Brain Cancer Drug
Press Release: Eli Lilly and Company Stops Trial Of Brain Cancer Drug
Read more...SPOTLIGHT: India OKs Peregrine trial
India has given Peregrine Pharmaceuticals a green light to conduct clinical trials of its experimental therapy Cotara for a type of brain cancer. "We believe this new clinical trial will be a cornerstone of our future plans to develop Cotara for the treatment of this deadly form of cancer," said Steven W. King, president and CEO of Peregrine. "We are moving this program forward in India because of the high level of experience of the participating neurosurgeons with CED delivery, the …
Read more...Schering-Plough to pay $435M in fines
Plagued by allegations that the company engaged in illegal marketing tactics and overcharged Medicaid for its drugs, Schering-Plough has agreed to pay $435 million to resolve criminal and civil investigations. Of that, Schering-Plough will fork over $255 million to settle civil claims while its subsidiary, Schering Sales Corp., will pay $180 million in criminal fines while pleading guilty to a conspiracy to lie to government investigators probing the marketing of a brain cancer …
Read more...Get more brain cancer coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets